Is Serum Caveolin-1 a Useful Biomarker for Progression in Patients with Colorectal Cancer?

Basit Öğe Kaydı
dc.authoridSahin, Abdullah Fahri/0000-0003-0196-2319|BEDIR, ABDULKERIM/0000-0002-7466-952X|Kocabas, Ramazan/0000-0002-7861-258X
dc.contributor.authorErdemli, Haci Kemal
dc.contributor.authorKocabas, Ramazan
dc.contributor.authorSalis, Osman
dc.contributor.authorSen, Fatma
dc.contributor.authorAkyol, Sumeyya
dc.contributor.authorEskin, Fatih
dc.contributor.authorAkyol, Omer
dc.date.accessioned2025-10-24T18:10:14Z
dc.date.available2025-10-24T18:10:14Z
dc.date.issued2016
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackground: Colorectal cancer (CRC) is the third most common cause of cancer diagnosed in males and the second in females. Survival is strongly related to stage at diagnosis. There is an urgent need to find a noninvasive biomarker that can be commonly applied for screening diagnosis, early detection of recurrence, and monitoring of metastatic CRC. Protein caveolin-1 (CAV-1) has been known to be expressed abnormally in colon cancer and appears to contribute to aberrant signaling and protein trafficking. There are controversial results regarding the role of CAV-1 in cancer. We hypothesized that levels of CAV-1 in serum of patients with CRC might be important to estimate the progression of the disease. Therefore, the purpose of this study is to investigate whether serum CAV-1 might be used as a factor determining progression of CRC. Methods: A total of 61 patients with CRC (26 male, 35 female) and 46 controls (38 male, 8 female) were enrolled. Serum CAV-1 levels were measured by ELISA. The relationship between CAV-1 and progression-free survival (PFS) was analyzed with use of receiver operating characteristic (ROC) and Kaplan-Meier analysis. Results were given as median (95% CI). Mann-Whitney test was used for the comparison of groups. Results: CAV-1 levels were found to be 11.5 ng/mL (10.4 - 12.9) in CRC and 11.9 ng/mL (10.7 - 14.4) in controls (p = 0.465). The serum CAV-1 levels in CRC patients with disease progression and without progression were respectively 10.0 ng/mL (8.5 - 11.3) and 12.2 ng/mL (11.1 - 14.8) (p = 0.023). In ROC analysis, if CAV-1 levels are equal or lesser than 10.73 ng/mL, it might show presence of progression with a sensitivity 73.3% and specificity 66.7% in patients with CRC (area under the ROC curve (AUC) = 0.697, p = 0.005). The mean PFS time was found to be 29.7 months (19.8 - 39.7, 95% CI for the mean) in patients who have CAV-1 level <= 10.73 ng/mL and 61.9 months (44.2 - 79.6) in patients who have CAV-1 level > 10.73 ng/mL [hazard ratios (HR) with 95% CI = 3.49 (1.26 - 9.68) (p = 0.017)]. Conclusions: Our results strongly suggest that CAV-1 levels might be used as a marker to determine progression of CRC. When considered in combination with other biomarkers of CRC, CAV-1 is clinically informative and instructive.
dc.identifier.doi10.7754/Clin.Lab.2015.150719
dc.identifier.endpage408
dc.identifier.issn1433-6510
dc.identifier.issue3
dc.identifier.pmid27156330
dc.identifier.scopus2-s2.0-84969174944
dc.identifier.scopusqualityQ3
dc.identifier.startpage401
dc.identifier.urihttps://doi.org/10.7754/Clin.Lab.2015.150719
dc.identifier.urihttps://hdl.handle.net/20.500.12899/4056
dc.identifier.volume62
dc.identifier.wosWOS:000372668900019
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherClin Lab Publ
dc.relation.ispartofClinical Laboratory
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectcaveolin-1; colorectal cancer; biomarker; progression
dc.titleIs Serum Caveolin-1 a Useful Biomarker for Progression in Patients with Colorectal Cancer?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu